Pomalidomide Combined With Obinutuzumab in the Treatment of Patients With Relapsed/Refractory Indolent Lymphoma
Clinical trial NCT07441954 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT07441954
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2026-03-20
- Primary completion
- 2027-12-05
- Enrollment
- 53
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.